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Abstract
Background: The impact of alcohol septal ablation (ASA) on the survival of patients with 
drug-refractory obstructive hypertrophic cardiomyopathy (HCM) remains unresolved. The aim 
of this study was to compare survival after ASA vs. conservative therapy.
Methods: We studied a consecutive cohort of 274 patients with severe drug-refractory ob-
structive HCM, 229 in ASA group and 45 in conservative group. The primary endpoint was  
a composite of all-cause mortality and aborted cardiac arrest.
Results: With a median follow-up of 4.3 years, primary endpoint occurred in 13 (5.7%) pa-
tients in the ASA group, and 8 (17.8%) patients in the conservative group. The 5- and 10-year 
survival free from primary endpoint of the ASA group (94.5% and 93.0%, respectively) was 
significantly better than that of the conservative group (78.3% and 72.2%, respectively, log-rank 
p = 0.009). Independent determinants of primary endpoint were ASA therapy (hazard ratio 
[HR] 0.22; 95% confidence interval [CI] 0.08–0.60; p = 0.003) and maximal septal thickness 
(HR 1.14; 95% CI 1.03–1.27; p = 0.011).
Conclusions: In patients with severe drug-refractory obstructive HCM, survival after ASA is 
favorable and better than that of conservative therapy. ASA seems to improve survival. (Cardiol J  
2015; 22, 6: 657–664)
Key words: obstructive hypertrophic cardiomyopathy, alcohol septal ablation, 
medical therapy, conservative therapy, survival
Introduction
Hypertrophic cardiomyopathy (HCM) is the 
most common genetic heart disease of Mende-
lian Inheritance, with a prevalence of 0.2% in the 
general population [1]. Left ventricular outflow 
tract obstruction (LVOTO), defined as a resting 
or provocative intracavity pressure gradient of 
≥ 30 mm Hg, presents in about 70% of patients with 
HCM [2]. This hemodynamic disorder is associated 
with a variety of limiting symptoms and worse 
prognosis [3]. Medications (i.e. beta-blockers, 
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non-dihydropyridine calcium channel blockers, and 
disopyramide) are recommended firstly for symp-
tomatic patients, but many patients cannot benefit 
from medical therapy. For severe drug-refractory 
symptoms that are attributable to LVOTO, invasive 
therapies such as alcohol septal ablation (ASA) 
and myectomy can be used to relieve LVOTO and 
improve symptoms [4, 5].
Studies have demonstrated that survival rates 
after ASA and myectomy in experienced cent-
ers were similar [6–8]. And, as survival after 
myectomy, survival after ASA is also comparable 
with that of general population [8, 9]. These data 
support the notion that ASA may be another in-
tervention which improves survival of patients 
with obstructive HCM and severe drug-refractory 
symptoms. Direct comparisons of survival after 
ASA and medical therapy will extend evidence 
to support this notion. There are studies show-
ing better survival rates after ASA vs. medical 
therapy as well [10–12]. However, as there were 
inherent differences between the conservatively 
treated patients and patients undergoing invasive 
therapies with regard to pressure gradient and 
symptoms in these studies [10–12], the impact of 
ASA on the survival of patients with HCM, severe 
drug-refractory symptoms and significant LVOTO 
remains unsolved. This study will compare the 
survival of patients undergoing ASA vs. a group 
of conservatively treated patients with comparable 
pressure gradient and limiting symptoms.
Methods
Study population
This study consecutively enrolled adult 
(≥ 18 years of age at initial presentation to Fuwai 
Hospital) patients with HCM, severe limiting 
symptoms (New York Heart Association [NYHA] 
functional class III/IV, Canadian Cardiovascular So-
ciety [CCS] class III/IV, or repetitive and disabling 
effort-related syncope) despite or unable to toler-
ate optimal medication treatment (beta-blockers 
[titrated to a resting heart rate of approximately 
60 bpm], verapamil [maximum 480 mg/day], diltiazem 
[maximum 360 mg/day]), a pressure gradient of 
≥ 50 mm Hg at rest or with provocation (or both), 
and without a history of previous ASA, myectomy 
or dual chamber (DDD) pacing before their first 
admission to Fuwai Hospital between January 2002 
and December 2012. The diagnosis of HCM was 
based on the presence of left ventricular maximum 
wall thickness ≥ 15 mm in the absence of another 
disease capable of producing the degree of hyper-
trophy [13]. Echocardiographic data were obtained 
as previously described [14]. Left ventricular out-
flow tract (LVOT) pressure gradient was assessed 
using continuous wave Doppler echocardiography 
and cardiac catheterization [14–16].
Patients were classified into ASA and conserv-
ative groups based on the treatment strategies they 
received at their first admission to our hospital. 
The ASA group included patients who underwent 
ASA at their first admission. The conservative 
group included patients who were 1) indicated to 
undergo ASA but refused any invasive therapies 
to treat LVOTO; or 2) consented to receive ASA, 
but unsuitable for it because of no appropriate 
septal branches applicable, and refused myectomy 
and DDD pacing. Patients refused one or more 
invasive therapies for their fear of operation risk 
or economic reasons. For patients in the conserva-
tive group, only medications were used to treat 
LVOTO-related limiting symptoms.
If a patient was treated conservatively because 
of any of the following conditions, which would 
the patient unsuitable for ASA and essentially not 
comparable to patients in the ASA group, then they 
were excluded: severe coronary artery disease, 
acute myocardial infarction (MI), mid-ventricular 
obstruction, extreme hypertrophy (≥ 30 mm), 
diffused hypertrophy, moderate-to-severe mitral 
regurgitation, renal dysfunction, hyperthyroid-
ism, hypothyroidism, liver dysfunction, malignant 
tumor, blood disease, massive pericardial effusion, 
Alzheimer’s disease, recent stroke, severe hyper-
tension, severe chronic obstructive pulmonary 
disease, or advanced age.
Alcohol septal ablation
All patients who received ASA presented 
a LVOT pressure gradient of ≥ 50 mm Hg at rest or 
with provocation, associated with drug-refractory 
NYHA functional class III/IV, CCS class III/IV, or 
repetitive and disabling effort-related syncope. 
ASA was performed using previously described 
techniques [17]. Intracoronary echo-contrast agent 
was used for the evaluation of target septal branch 
for all patients undergoing ASA.
Follow-up and definition of endpoints
The primary endpoint was a composite of 
death from any cause and aborted cardiac arrest. 
The secondary endpoint was the invasive treat-
ment of LVOTO during follow-up, including ASA, 
myectomy, and DDD pacing. The following condi-
tions were considered to be cardiovascular death 
[18]: 1) procedural mortality of ASA, myectomy, 
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and DDD pacing (deaths within 30 days after 
these procedures); 2) sudden cardiac death (SCD; 
unexpected within 1 h of witnessed collapse or 
nocturnal in previously stable patients); 3) heart 
failure-related death (in context of progressive 
cardiac decompensation); 4) stroke-related death 
(defined according to standard criteria [19]); or 
5) fatal MI [20]. Death which occurred within 30 days 
after an invasive procedure is also counted as SCD, 
heart failure-related death, stroke-related death, or 
fatal MI, if corresponding criteria are met.
The follow-up of patients in the conservative 
group started at their first admission on January 
1, 2002. For patients in the ASA group, the follow-
up started on the day of operation. The endpoint 
status was ascertained by follow-up evaluation, 
including medical records, clinic visits, mailed 
questionnaires, telephone contact, short message, 
and Internet based instant messenger WeChat 
(Tencent, Inc., Shenzhen, Guangdong). For de-
ceased patients, procurement of death certificates 
and interviews with next of kin was performed to 
determine the cause and time of death.
This study was approved by the local Ethics 
Committee with patient informed consent.
Statistical analysis
Continuous variables were expressed as mean 
± standard deviation (SD) or median (interquartile 
range [IQR]), and differences between groups were 
analyzed by t test or Mann-Whitney U test, where 
appropriate. Categorical variables were summa-
rized as frequencies with percentages and were 
compared by Pearson c2 test, Fisher’s exact test 
or continuity correction c2 test, where appropri-
ate. Univariate and multivariate Cox regression 
analyses were used to identify clinical predictors 
of endpoints. Variables with univariate p values 
< 0.10 were selected for multivariate analysis 
and were expressed as hazard ratios (HRs) with 
95% confidence intervals (CIs). Multivariate Cox 
regression analysis was performed using backward 
stepwise method. The final number of variables in 
multivariate model was restricted according to the 
number of endpoint events to avoid overfitting. The 
following variables were evaluated: age, gender, 
coronary artery disease, hypertension, diabetes 
mellitus, atrial fibrillation, prior stroke, syncope/
presyncope, baseline left atrium diameter, base-
line left ventricular diameter, baseline maximal 
septal thickness, baseline pressure gradient, and 
baseline ejection fraction. Kaplan-Meier survival 
curves were constructed to represent the survival 
graphically. Differences in survival between the 
groups were compared with log-rank test. When 
analyzing predictors of primary endpoint and com-
paring the survival free from primary endpoint, data 
on patients who received invasive treatment for 
LVOTO during follow-up period were censored at 
the date of their first procedure during the follow-
up (i.e. the second invasive procedure for patients 
in ASA group, or the first invasive procedure for 
patients in conservative group). Data on patients 
who experienced aborted cardiac arrest were not 
censored at the date of resuscitation when analyz-
ing predictors of secondary endpoint and compar-
ing the survival free from secondary endpoint. All 
analyses were performed with SPSS statistical 
software, version 16.0 (SPSS Inc., Chicago, IL). 
All tests were 2-tailed, and statistical significance 
was defined as a p < 0.05.
Results
Baseline characteristics
Medical records of 2,207 patients with HCM 
were screened. A total of 274 patients with HCM, 
severe drug-refractory symptoms, and a pressure 
gradient of ≥ 50 mm Hg met the include/exclude 
criteria of this study and were all enrolled, 229 
patients in the ASA group, 45 in the conservative 
group. Table 1 lists the baseline characteristics 
of patients in ASA group (age: 49.8 ± 9.7 years; 
62.4% male) and conservative group (age: 52.5 ± 
± 11.8 years; 60.0% male). The prevalence of 
NYHA class III/IV dyspnea, CCS class III/IV angina, 
and syncope/presyncope was similar between the 
two groups. No significant differences of baseline 
LVOT pressure gradient, medications, and comor-
bidities were observed.
Acute procedural results and  
30-day periprocedural complications
Septal ablation resulted in a median resid-
ual resting LVOT gradient of 25.0 mm Hg (IQR 
30.0 mm Hg). Two (0.9%) patients in the ASA group 
died from procedural complications of ASA. One 
died from ventricular fibrillation (VF), the other 
for hemorrhagic shock caused by retroperitoneal 
hematoma. VF occurred immediately after alcohol 
injection in 2 patients, both of whom were suc-
cessfully resuscitated. VF attacked another patient 
2 days after ASA, who was also successfully resus-
citated. No more cardiac arrests occurred in these 
3 patients and they were still alive at the last fol-
low-up. The leakage of alcohol into communicating 
branches resulted in acute MI beyond target region 
in 2 (0.9%) patients; 1 died from VF 11 days after 
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the procedure as mentioned above, the other was 
still alive at the most recent follow-up. Complete 
atrioventricular block occurred in 101 (44.1%) 
patients (Table 2). Nevertheless, atrioventricular 
conduction restored in all of these patients before 
discharge, and no new permanent pacemaker de-
pendency occurred. Cardiac tamponade occurred 
in 2 (0.9%) patients and they were all successfully 
treated with pericardiocentesis.
Endpoints
The follow-up was completed in 274 (100%) 
patients with a median follow-up of 4.3 years 
(mean: 4.9 years; range: 3 days to 12.6 years; 
a total of 1,344 patient-years). As shown in Table 3, 
primary endpoint occurred in 21 (7.7%) patients 
during the follow-up period (1.6% per year), 8 in 
the conservative group (4.0% per year), and 13 in 
the ASA group (1.1% per year). The occurrence 
of in-hospital primary endpoint of the ASA group 
was described above. No in-hospital mortality hap-
pened in the conservative group. Two patients in 
the ASA group received implantable cardioverter 
defibrillator implantation during the follow-up, 
but no discharge events occurred. A total of 
Table 1. Baseline variables.
Conservative
(n = 45)
ASA
(n = 229)
P
Age [years] 52.5 ± 11.8 49.8 ± 9.7 0.105
Male 27 (60.0%) 143 (62.4%) 0.757
NYHA class III/IV 20 (44.4%) 120 (52.4%) 0.329
CCS class III/IV 16 (35.6%) 80 (34.9%) 0.936
Syncope/presyncope 16 (35.6%) 109 (47.6%) 0.138
Atrial fibrillation 8 (17.8%) 19 (8.3%) 0.093
Prior stroke 2 (4.4%) 6 (2.6%) 0.857
Hypertension 13 (28.9%) 69 (30.1%) 0.868
Diabetes mellitus 1 (2.2%) 12 (5.2%) 0.626
Coronary artery disease 4 (8.9%) 22 (9.6%) > 0.999 
Maximum septal thickness [mm] 21.1 ± 3.4 22.3 ± 4.3 0.076
End-diastolic diameter [mm] 43.7 ± 5.7 41.7 ± 5.3 0.024
LVEF [mm] 67.2 ± 8.5 71.6 ± 7.8 0.001
Left atrium [mm] 43.3 ± 7.8 41.5 ± 6.2 0.156
Resting LVOT pressure gradient [mm Hg] 90.4 ± 35.5 91.5 ± 36.0 0.856
Baseline medications:
Beta-blocker 41 (91.1%) 192 (83.8%) 0.211
Calcium channel blocker 18 (40.0%) 60 (26.2%) 0.061
ASA — alcohol septal ablation; CCS — Canadian Cardiovascular Society; LVEF — left ventricular ejection fraction; LVOT — left ventricular  
outflow tract; NYHA — New York Heart Association; SD — standard deviation
Table 2. Procedure data (n = 229).
Variables Value
Residual resting pressure gradient, 
median (IQR) [mm Hg]
25.0 (30.0)
Reduction in LVOT pressure  
gradient (SD) [%]
71.6 (19.0)
Complete atrioventricular block 101 (44.1%)
Cardiac tamponade 2 (0.9%)
Ablated branches:
First septal branch 166 (72.5%)
Second septal branch 81 (35.4%)
Third septal branch 11 (4.8%)
Fourth septal branch 1 (0.4%)
Second diagonal branch 3 (1.3%)
Branch of left circumflex 2 (0.9%)
Number of ablated branches:
One 196 (85.6%)
Two 31 (13.5%)
Three 2 (0.9%)
Volume of alcohol injected,  
median (IQR) [mL]
2.4 (1.6)
IQR — interquartile range; LVOT — left ventricular outflow tract;  
SD — standard deviation
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24 patients underwent invasive procedures to treat 
LVOTO during the follow-up, 15 in the ASA group, 
and 9 in the conservative group. No periprocedural 
mortality occurred after these procedures. One 
patient in the conservative group who received 
DDD pacing at 1.6 years of follow-up died at 
7.4 years of follow-up. One patient in ASA group who 
received the second ASA procedure at 1.7 years 
of follow-up died at 8.9 years of follow-up. Other 
22 patients who underwent invasive procedures to 
treat LVOTO during follow-up were still alive at 
the last follow-up.
Cox proportional analysis showed that the inde-
pendent predictors of primary endpoint were ASA 
therapy (HR 0.22; 95% CI 0.08–0.60; p = 0.003) 
and maximal septal thickness (HR 1.14; 95% CI 
1.03–1.27; p = 0.011). Independent predictors of sec-
ondary endpoint were ASA therapy (HR 0.25; 95% 
CI 0.11–0.59; p = 0.001) and syncope/presyncope 
(HR 2.68; 95% CI 1.14–6.29; p = 0.023) (Table 4). 
Table 3. Endpoint.
Conservative
(n = 45)
ASA
(n = 229)
P 
Primary endpoint 8 (17.8%) 13 (5.7%) 0.013
All-cause mortality 8 (17.8%) 10 (4.4%) 0.003
Cardiovascular death 8 (17.8%) 9 (3.9%) 0.001
Sudden cardiac death 1 (2.2%) 2 (0.9%) 0.417
Heart failure-related death 5 (11.1%) 2 (0.9%) 0.001
Stroke-related death 1 (2.2%) 3 (1.3%) 0.514
Alcohol septal ablation-related death NA 2 (0.9%) NA
Fatal myocardial infarction 1 (2.2%) 0 (0%) 0.164
Non-cardiovascular death 0 (0%) 1 (0.4%) > 0.999
Cancer-related death 0 (0%) 1 (0.4%) > 0.999
Aborted cardiac arrest 0 (0%) 3 (1.3%) > 0.999
Secondary endpoint 9 (20.0%) 15 (6.6%) 0.009
Alcohol septal ablation 4 (8.9%) 4 (1.7%) 0.034
Myectomy 2 (4.4%) 10 (4.4%) > 0.999
Dual chamber pacing 3 (6.7%) 1 (0.4%) 0.015
Primary endpoint is a composite of death from any cause and aborted cardiac arrest. Secondary endpoint is the invasive treatments of left 
ventricular outflow obstruction during follow-up, including alcohol septal ablation, myectomy, and dual chamber pacing; ASA — alcohol  
septal ablation; NA — not applicable
Table 4. Predictors of primary and secondary endpoints.
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Primary endpoint
Age 1.01 (0.97–1.06) 0.632 – –
Female 2.07 (0.84–5.10) 0.115 – –
Alcohol septal ablation 0.31 (0.12–0.78) 0.013 0.22 (0.08–0.60) 0.003
Maximal septal thickness 1.11 (1.00*–1.22) 0.041 1.14 (1.03–1.27) 0.011
Secondary endpoint
Age 1.00* (0.96–1.04) 0.938 – –
Female 0.58 (0.23–1.47) 0.254 – –
Alcohol septal ablation 0.28 (0.12–0.64) 0.003 0.25 (0.11–0.59) 0.001
Syncope/presyncope 2.43 (1.04–5.68) 0.040 2.68 (1.14–6.29) 0.023
Primary and secondary endpoints are defined as in Table 3; CI — confidence interval; HR — hazard ratio; *> 1.00
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Kaplan-Meier estimates of survival free from pri-
mary and secondary endpoints are shown in Fig-
ures 1 and 2. The 1-year survival free from primary 
endpoint of the ASA group was slightly numerically 
lower than that of the conservative group (97.4% 
vs. 97.7%). The 5- and 10-year survival rates free 
from primary endpoint in the ASA (94.5% and 
93.0%, respectively) group were greater than that 
in the conservative group (78.3% 5-year, and 72.2% 
at 10 years; log-rank p = 0.009) (Fig. 1). The ASA 
group also experienced superior survival free from 
secondary endpoint than the conservative group 
(98.2% 1-year, 93.8% 5-year, and 88.7% at 10 years 
vs. 91.0% 1-year, 77.7% 5-year, and 77.7% at 
10 years; log-rank p = 0.001) (Fig. 2).
Discussion
This report describes the survival after ASA 
compared with conservative therapy in patients 
with HCM, severe drug-refractory limiting symp-
toms, and a pressure gradient of ≥ 50 mm Hg at 
rest or with provocation at a tertiary referral center 
in China. The main findings of our study are: 
1) survival of patients treated with ASA is better 
than that of conservative therapy; 2) ASA is inde-
pendently associated with survival.
Alcohol septal ablation, an interventional 
technique designed to improve limiting symptoms 
by inducing relief of LVOTO, has been applied for 
nearly 20 years [16]. However, we are still not 
sure whether this technique extends longevity of 
its target patients. Results from several studies 
suggest that ASA can extend longevity of patients 
with HCM [6–12]. Here, we extended evidence for 
this notion by directly comparing the survival of 
patients undergoing ASA vs. a group of conserva-
tively treated patients with comparable pressure 
gradient and limiting symptoms.
Periprocedural mortality of ASA in this study 
(0.9%) was low and comparable to that of other 
tertiary referral centers [8, 11, 21, 22]. No further 
lethal ventricular arrhythmia occurred in the three 
successfully resuscitated patients during follow-up 
suggested the prognostic significance of periproce-
dural cardiac arrest was limited, which agreed with 
Figure 1. Survival free from primary endpoint after al-
cohol septal ablation (ASA) compared with the con-
servative (CONS.) group (log-rank p = 0.009). Primary 
endpoint is a composite of death from any cause and 
aborted cardiac arrest.
Figure 2. Survival free from secondary endpoint of the 
alcohol septal ablation (ASA) group compared with the 
conservative (CONS.) group (log-rank p = 0.001). Sec-
ondary endpoint is the invasive treatments of left ven-
tricular outflow obstruction during follow-up, including 
ASA, myectomy, and dual chamber pacing.
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the role of VF complicating acute MI [21, 23, 24]. 
Additionally, the numerically lower 1-year survival 
free from primary endpoint of ASA vs. conservative 
group (97.4% vs. 97.7%) was associated with mor-
tality and aborted cardiac arrest occurred during 
the perioperative period in ASA group, whereas, 
in the conservative group, no in-hospital primary 
endpoint occurred.
The relatively better survival of the ASA 
group in this study vs. several previous reports 
may be explained by the fact that patients in the 
ASA group of our study were younger (mean age: 
49.8 years) than those from the other studies 
(mean age: 54–64 years) [8, 25–27]. There were 
reports demonstrating the survival advantage of 
patients younger than 60 years or 65 years [25, 28]. 
Besides, survival of the ASA group in this study 
was comparable to one cohort with a mean age of 
< 50 years, which supports this viewpoint as well 
[29]. It is not surprising that the survival of the 
conservative group was not only worse than the 
one of the ASA group in this study, but also worse 
than conservatively treated groups in two recent 
studies [11, 12]. In both studies, the conservatively 
treated patients were less symptomatic and with 
lower pressure gradient. The survival advantage of 
ASA vs. conservative group suggests the survival 
disadvantage associated with LVOTO can be offset, 
at least partially, by ASA [3].
The incidence of new permanent pacemaker 
implantation in this study was low (0%). This may 
be associated with the applying of myocardial 
contrast echocardiography and the prudent use 
of alcohol during ASA. Moreover, ASA is only 
performed by or performed under the guidance 
of the most experienced invasive operators in our 
institution, ensuring high safety of the procedure.
Several studies suggested age as an independ-
ent predictor of adverse events [8, 21, 25, 28], 
whereas Cox regression analysis did not identify 
this variable as an independent risk factor of pri-
mary or secondary end point in this study, which 
was in line with Veselka et al. [29]. We should note 
that age-related adverse events mainly occurred in 
patients older than 60 years [8, 25, 28]. Moreover, 
the mean age of our study population at enroll-
ment was only about 50 years. This meant that 
the majority of our patients were still less than 
60 years of age after a median follow-up of 
4.3 years. Consequently, the role of age as an inde-
pendent risk factor may not emerge in this age group.
No wonder a higher proportion of patients 
in the conservative group underwent invasive 
procedures to treat LVOTO during the follow-up. 
These patients finally chose to receive invasive 
therapies because of disease progression, change 
in attitude, or getting enough money to afford inva-
sive treatments. Interestingly, in the conservative 
group, the proportions of patients undergoing ASA, 
myectomy, or DDD pacing during the follow-up did 
not differ much, whereas, in the ASA group, there 
were obviously more patients who chose to receive 
myectomy than patients who chose to receive ASA 
and DDD pacing. This suggested a treatment pref-
erence shift after the first ASA procedure. Patients 
who experienced ASA seem more likely to choose 
myectomy when they need a second septal reduc-
tion procedure. This should be associated with the 
fact that myectomy has been demonstrated to bring 
a better relief of LVOTO [4, 5].
Limitations of the study
Some study limitations have to be acknowl-
edged. First, this was a nonrandomized, retro-
spective cohort study. However, it is unlikely that 
a prospective randomized controlled trial comparing 
the outcome of conservative therapy vs. ASA will 
ever be conducted [30]. Second, as our data were 
retrieved from a tertiary referral center, there 
might also be a referral bias. The procedural re-
sults reported here represent those achieved by 
an experienced ASA referral center and therefore 
constitute a measure of the most favorable outcome 
that can be expected from ASA. It is inappropriate 
to extrapolate these findings to low-volume ASA 
centers. Third, the sample size of conservative 
group was relatively small. This is because only 
a very small proportion of patients who were in-
dicated to invasive treatments will choose to give 
up or refuse these procedures in clinical practice. 
Finally, as disopyramide is not available in China, 
no patients in our study were treated with this 
medication.
Conclusions
This study suggests that in patients with 
HCM, severe drug-refractory symptoms and sig-
nificant LVOTO, survival after ASA is favorable and 
better than that in patients treated conservatively. 
Thus, ASA seems to improve survival.
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